US Pharma MarketingAn analysis of how innovative American biotech firms can maintain their competitive edge against rising international competition and market shifts. But the investing weather has changed: there is now greater caution both from U.S. regulators and investors, which has dovetailed with both a surplus of capital and increased regulatory streamlining in China. This creates an even challenging environment for innovative biotech firms. The key, then, is for U.S. biotech to forge a new path that navigates the challenge of IP appropriation by lower cost Chinese firms, maximizing investment in drug development areas viewed as popular and low risk, or finding…
For the past several years, success has grown more elusive for American biotech firms. Even in the more robust investment climates prior to 2022, developing and growing a biotech always required a combination of risk appetite and patient capital that did not lend itself to the rapid exits typical of other areas of tech investing. …
The post Blazing new paths for biotech appeared first on Drug Discovery and Development.
Source: Drug Discovery & Development